Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis

Bharath Wootla, Jens O. Watzlawik, Nikolaos Stavropoulos, Nathan J. Wittenberg, Harika Dasari, Murtada A. Abdelrahim, John R Henley, Sang Hyun Oh, Arthur E. Warrington, Moses Rodriguez

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Introduction: Multiple sclerosis (MS) is the most common chronic inflammatory, demyelinating disease of the CNS and results in neurological disability. Existing immunomodulatory and immunosuppressive approaches lower the number of relapses but do not cure or reverse existing deficits nor improve long-term disability in MS patients. Areas Covered: Monogenic antibodies were described as treatment options for MS, however the immunogenicity of mouse antibodies hampered the efficacy of potential therapeutics in humans. Availability of improved antibody production technologies resulted in a paradigm shift in MS treatment strategies. In this review, an overview of immunotherapies for MS that use conventional monoclonal antibodies reactive to immune system and their properties and mechanisms of action will be discussed, including recent advances in MS therapeutics and highlight natural autoantibodies (NAbs) that directly target CNS cells. Expert Opinion: Recent challenges for MS therapy are the identification of relevant molecular and cellular targets, time frame of treatment, and antibody toxicity profiles to identify safe treatment options for MS patients. The application of monoclonal antibody therapies with better biological efficacy associated with minimum side effects possesses huge clinical potential. Advances in monoclonal antibody technologies that directly target cells of nervous system may promote the CNS regeneration field from bench to bedside.

Original languageEnglish (US)
Pages (from-to)1-13
Number of pages13
JournalExpert Opinion on Biological Therapy
DOIs
StateAccepted/In press - Mar 11 2016

Fingerprint

Multiple Sclerosis
Monoclonal Antibodies
Antibodies
Immune system
Neurology
Therapeutics
Immunosuppressive Agents
Autoantibodies
Toxicity
Availability
Technology
Expert Testimony
Demyelinating Diseases
Immunotherapy
Nervous System
Antibody Formation
Regeneration
Immune System
Recurrence

Keywords

  • clinical studies
  • immunogenicity
  • mAbs
  • monoclonal antibodies
  • Multiple sclerosis
  • safety

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery

Cite this

Wootla, B., Watzlawik, J. O., Stavropoulos, N., Wittenberg, N. J., Dasari, H., Abdelrahim, M. A., ... Rodriguez, M. (Accepted/In press). Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis. Expert Opinion on Biological Therapy, 1-13. https://doi.org/10.1517/14712598.2016.1158809

Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis. / Wootla, Bharath; Watzlawik, Jens O.; Stavropoulos, Nikolaos; Wittenberg, Nathan J.; Dasari, Harika; Abdelrahim, Murtada A.; Henley, John R; Oh, Sang Hyun; Warrington, Arthur E.; Rodriguez, Moses.

In: Expert Opinion on Biological Therapy, 11.03.2016, p. 1-13.

Research output: Contribution to journalArticle

Wootla, B, Watzlawik, JO, Stavropoulos, N, Wittenberg, NJ, Dasari, H, Abdelrahim, MA, Henley, JR, Oh, SH, Warrington, AE & Rodriguez, M 2016, 'Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis', Expert Opinion on Biological Therapy, pp. 1-13. https://doi.org/10.1517/14712598.2016.1158809
Wootla B, Watzlawik JO, Stavropoulos N, Wittenberg NJ, Dasari H, Abdelrahim MA et al. Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis. Expert Opinion on Biological Therapy. 2016 Mar 11;1-13. https://doi.org/10.1517/14712598.2016.1158809
Wootla, Bharath ; Watzlawik, Jens O. ; Stavropoulos, Nikolaos ; Wittenberg, Nathan J. ; Dasari, Harika ; Abdelrahim, Murtada A. ; Henley, John R ; Oh, Sang Hyun ; Warrington, Arthur E. ; Rodriguez, Moses. / Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis. In: Expert Opinion on Biological Therapy. 2016 ; pp. 1-13.
@article{457ac952e7844e22a16bab1859ddf1e0,
title = "Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis",
abstract = "Introduction: Multiple sclerosis (MS) is the most common chronic inflammatory, demyelinating disease of the CNS and results in neurological disability. Existing immunomodulatory and immunosuppressive approaches lower the number of relapses but do not cure or reverse existing deficits nor improve long-term disability in MS patients. Areas Covered: Monogenic antibodies were described as treatment options for MS, however the immunogenicity of mouse antibodies hampered the efficacy of potential therapeutics in humans. Availability of improved antibody production technologies resulted in a paradigm shift in MS treatment strategies. In this review, an overview of immunotherapies for MS that use conventional monoclonal antibodies reactive to immune system and their properties and mechanisms of action will be discussed, including recent advances in MS therapeutics and highlight natural autoantibodies (NAbs) that directly target CNS cells. Expert Opinion: Recent challenges for MS therapy are the identification of relevant molecular and cellular targets, time frame of treatment, and antibody toxicity profiles to identify safe treatment options for MS patients. The application of monoclonal antibody therapies with better biological efficacy associated with minimum side effects possesses huge clinical potential. Advances in monoclonal antibody technologies that directly target cells of nervous system may promote the CNS regeneration field from bench to bedside.",
keywords = "clinical studies, immunogenicity, mAbs, monoclonal antibodies, Multiple sclerosis, safety",
author = "Bharath Wootla and Watzlawik, {Jens O.} and Nikolaos Stavropoulos and Wittenberg, {Nathan J.} and Harika Dasari and Abdelrahim, {Murtada A.} and Henley, {John R} and Oh, {Sang Hyun} and Warrington, {Arthur E.} and Moses Rodriguez",
year = "2016",
month = "3",
day = "11",
doi = "10.1517/14712598.2016.1158809",
language = "English (US)",
pages = "1--13",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis

AU - Wootla, Bharath

AU - Watzlawik, Jens O.

AU - Stavropoulos, Nikolaos

AU - Wittenberg, Nathan J.

AU - Dasari, Harika

AU - Abdelrahim, Murtada A.

AU - Henley, John R

AU - Oh, Sang Hyun

AU - Warrington, Arthur E.

AU - Rodriguez, Moses

PY - 2016/3/11

Y1 - 2016/3/11

N2 - Introduction: Multiple sclerosis (MS) is the most common chronic inflammatory, demyelinating disease of the CNS and results in neurological disability. Existing immunomodulatory and immunosuppressive approaches lower the number of relapses but do not cure or reverse existing deficits nor improve long-term disability in MS patients. Areas Covered: Monogenic antibodies were described as treatment options for MS, however the immunogenicity of mouse antibodies hampered the efficacy of potential therapeutics in humans. Availability of improved antibody production technologies resulted in a paradigm shift in MS treatment strategies. In this review, an overview of immunotherapies for MS that use conventional monoclonal antibodies reactive to immune system and their properties and mechanisms of action will be discussed, including recent advances in MS therapeutics and highlight natural autoantibodies (NAbs) that directly target CNS cells. Expert Opinion: Recent challenges for MS therapy are the identification of relevant molecular and cellular targets, time frame of treatment, and antibody toxicity profiles to identify safe treatment options for MS patients. The application of monoclonal antibody therapies with better biological efficacy associated with minimum side effects possesses huge clinical potential. Advances in monoclonal antibody technologies that directly target cells of nervous system may promote the CNS regeneration field from bench to bedside.

AB - Introduction: Multiple sclerosis (MS) is the most common chronic inflammatory, demyelinating disease of the CNS and results in neurological disability. Existing immunomodulatory and immunosuppressive approaches lower the number of relapses but do not cure or reverse existing deficits nor improve long-term disability in MS patients. Areas Covered: Monogenic antibodies were described as treatment options for MS, however the immunogenicity of mouse antibodies hampered the efficacy of potential therapeutics in humans. Availability of improved antibody production technologies resulted in a paradigm shift in MS treatment strategies. In this review, an overview of immunotherapies for MS that use conventional monoclonal antibodies reactive to immune system and their properties and mechanisms of action will be discussed, including recent advances in MS therapeutics and highlight natural autoantibodies (NAbs) that directly target CNS cells. Expert Opinion: Recent challenges for MS therapy are the identification of relevant molecular and cellular targets, time frame of treatment, and antibody toxicity profiles to identify safe treatment options for MS patients. The application of monoclonal antibody therapies with better biological efficacy associated with minimum side effects possesses huge clinical potential. Advances in monoclonal antibody technologies that directly target cells of nervous system may promote the CNS regeneration field from bench to bedside.

KW - clinical studies

KW - immunogenicity

KW - mAbs

KW - monoclonal antibodies

KW - Multiple sclerosis

KW - safety

UR - http://www.scopus.com/inward/record.url?scp=84961219009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961219009&partnerID=8YFLogxK

U2 - 10.1517/14712598.2016.1158809

DO - 10.1517/14712598.2016.1158809

M3 - Article

C2 - 26914737

AN - SCOPUS:84961219009

SP - 1

EP - 13

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

ER -